Studies indicate that VivoSight OCT reliably predicts tumour margins

17 Jan 2013 – Accurate determination of tumour margins is vital to the successful treatment of skin cancer patients. This is especially the case for patients undergoing Mohs Micrographic Surgery where complete tumour removal may require repeated invasive procedures.

Recent studies conducted in two US Healthcare facilities used the VivoSight OCT scanner, manufactured in the UK by Michelson Diagnostics Ltd, to prospectively refine clinically estimated tumour margins prior to Mohs Micrographic Surgery.

The first 52 patient study 1 conducted by Professor Dan Seigel  (Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, New York) concluded that:

“OCT assessment has the potential to reduce the excised area without compromising the integrity of tumour-free borders.”

Click here to download a copy of the full press release.